Literature DB >> 15538090

Hyperkeratosis of the heels: treatment with salicylic acid in a novel delivery system.

Joseph Bikowski1.   

Abstract

A 43-year-old woman presented with dryness and scaling of the lateral and posterior aspects of both heels, which was diagnosed as hyperkeratotic xerosis (Figure 1). Pertinent medical history included dry skin with winter exacerbation and painful hyperkeratosis of the heels present for many years. The patient applied a topical multivesicular cream formulation of 6% salicylic add (Salex, Healthpoint Ltd., Fort Worth, TX) to one foot b.i.d. The physician was blinded as to which foot was treated. After 2 weeks of treatment, it was apparent that the patient was applying the cream to the right foot, as evidenced by reduced dryness, scaling, and hyperkeratosis (Figure2). The patient continued treatment of the same foot for an additional 2 weeks, revealing a dramatic improvement of the right heel,which appeared smooth and soft and devoid of pain. No irritation was associated with treatment; the patient commented that this was the best her heel had been "in years." Subsequently, the patient treated both heels with salicylic acid 60%, multivesicular cream. A second patient, a 25-year-old woman, was treated for ichthyosis vulgaris and hyperkeratosis of both heels. She presented w ith multiple painful fissures and hyperkeratosis of the posterior heels bilaterally (Figure 3). After I week of topical treatment with salicylic add 6%, multivesicular cream applied b.i.d. to the left heel only, there was rapid resolution of both hyperkeratosis and pain (Figure 4).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15538090     DOI: 10.1111/j.1540-9740.2004.04056.x

Source DB:  PubMed          Journal:  Skinmed        ISSN: 1540-9740


  4 in total

1.  Lanolin-based organogel of salicylic acid: evidences of better dermatokinetic profile in imiquimod-induced keratolytic therapy in BALB/c mice model.

Authors:  Gajanand Sharma; Neelam Devi; Kanika Thakur; Ashay Jain; O P Katare
Journal:  Drug Deliv Transl Res       Date:  2018-04       Impact factor: 4.617

Review 2.  Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.

Authors:  C Porta; C Paglino; I Imarisio; L Bonomi
Journal:  Clin Exp Med       Date:  2008-01-11       Impact factor: 3.984

3.  The reliability of non-invasive biophysical outcome measures for evaluating normal and hyperkeratotic foot skin.

Authors:  Farina Hashmi; Ciaran Wright; Christopher Nester; Sharon Lam
Journal:  J Foot Ankle Res       Date:  2015-07-09       Impact factor: 2.303

4.  Characterising the biophysical properties of normal and hyperkeratotic foot skin.

Authors:  Farina Hashmi; Christopher Nester; Ciaran Wright; Veronica Newton; Sharon Lam
Journal:  J Foot Ankle Res       Date:  2015-08-12       Impact factor: 2.303

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.